
    
      All participants who completed trial A3L24 (NCT01177722) will be recruited to participate in
      this trial. Those who received DTaP-IPV-Hep B-PRP-T combined vaccine will be randomized to
      receive either a booster dose of DTaP-IPV-Hep B-PRP-T or Infanrix hexa™ vaccine.

      Those who received Infanrix hexa™ will receive a booster dose of DTaP-IPV-Hep B-PRP-T
      combined vaccine. All participants will receive a booster dose of Prevenar™ concomitantly.
    
  